MOTS-c: The Mitochondrial Peptide Your Body Makes — and Stops Making With Age

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is unusual among research peptides for one reason: your body makes it naturally. It is encoded not in the cell's nuclear DNA but in mitochondrial DNA — the separate genetic material housed in the mitochondria. This discovery, published in 2015, revealed that mitochondria are not just energy-producing organelles but also signalling centres producing biologically active peptides.

What Mitochondria Actually Do

Mitochondria are the power plants of cells. They take glucose and fat and convert them into ATP — the molecular currency of cellular energy. Every biological process in your body runs on ATP. Mitochondrial function is therefore central to energy levels, physical capacity, metabolic health and, increasingly, to how cells age.

Mitochondrial dysfunction — reduced efficiency, increased free radical production, declining ATP output — is one of the most consistently observed hallmarks of aging across species and tissue types.

What MOTS-c Does

MOTS-c targets multiple metabolic pathways. Research has shown it activates AMPK (AMP-activated protein kinase), the cellular energy sensor that drives fat burning and glucose uptake in muscle tissue. In animal studies, MOTS-c supplementation produced improvements in insulin sensitivity, reduced diet-induced obesity, and enhanced exercise endurance even in sedentary animals.

Human data showed that circulating MOTS-c levels are significantly higher in exercising individuals compared to sedentary controls, and that levels correlate with measures of metabolic health. This suggests MOTS-c is part of the mechanism by which exercise improves metabolism — and that declining levels with age may partially explain why metabolic health deteriorates in less active older populations.

The Age-Related Decline

Like NAD+, MOTS-c levels decline measurably with age. Research in humans shows significantly lower circulating MOTS-c in older adults compared to younger people with similar activity levels. The combination of reduced MOTS-c and reduced NAD+ (both mitochondrial health markers that decline with age) creates a compelling rationale for why they appear together in longevity research stacks.

Research Status

MOTS-c is a relatively recently characterised compound — the foundational paper was published in 2015. Research is still in earlier stages compared to compounds with longer histories. The animal data is promising and the mechanism is well-characterised. Human clinical trials are limited. G&D Pharma supplies MOTS-c at 20mg for research purposes only.